Elicio Therapeutics (ELTX) Stock: Buy, Sell, or Hold?
ELTX - Elicio Therapeutics, Inc. Common Stock
$1.80
0.13 (7.49%)
â˛
5d:
+0.84%
30d:
-4.01%
90d:
-40.17%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 12, 2026
20d
Get Alerted When ELTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ELTX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ELTX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ELTX is currently trading at $1.79, which is considered fair relative to its 30-day fair value range of $1.71 to $1.94.
Technical Outlook: Technically, ELTX is in a strong downtrend. Immediate support is located at $1.44, while resistance sits at $1.92. The stock is showing strong short-term momentum, up 7.5% recently.
Market Sentiment: The stock scores a mixed 52/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.67 (+718.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ELTX is in a strong downtrend. Immediate support is located at $1.44, while resistance sits at $1.92. The stock is showing strong short-term momentum, up 7.5% recently.
Market Sentiment: The stock scores a mixed 52/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.67 (+718.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.71 -
$1.94
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (52/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.5%)
- BULLISH: Trading 718.4% below Wall St target ($13.67)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.71 -
$1.94
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.44
Resistance Level
$1.92
Current Trend
Strong Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.99
Wall Street Target
$13.67
(+718.4%)
Share & Embed Analysis
Last updated: October 22, 2026 10:08 AM ET
Data refreshes hourly during market hours. Next update: 11:08 AM
Data refreshes hourly during market hours. Next update: 11:08 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
28 analysts |
$92 | 72 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 70 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 76 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 51 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 64 BUY |
